The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft modelsSarah V. Holt, Paul D. Smith|British Journal of Cancer|2012Cited by 111
Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinaseXiaoyong Fu, Rachel Schiff, Alejandro Contreras et al.|Breast Cancer Research|2014Cited by 70
Pharmaceutical Reactivation of Attenuated Apoptotic Pathways Leads to Elimination of Osimertinib Drug-Tolerant CellsMatthew J. Martin, Paul D. Smith|Cancer Research Communications|2022Cited by 8